Avirmax Inc. to Make Scientific Presentations at ASGCT in Baltimore

HAYWARD, Calif., April 15, 2024 ~ Avirmax Inc. is set to make a significant impact at the upcoming American Society of Gene and Cell Therapy (ASGCT) annual meeting in Baltimore, which will take place from May 7th to 11th, 2024. The company will be presenting two scientific presentations and showcasing their latest progress and data package at exhibitor booth #818.

The ASGCT is the largest international society dedicated to understanding, development, and application of gene and cell therapy. Avirmax's presentations will be focused on their lead candidate ABI-110 for wet age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV). The first presentation, titled "Macular retina-targeting AAV capsid identified through multi-species screening in mice, rabbits, pigs, and monkeys," will be given by Li Ou, Ph.D. during the session on AAV Capsid Engineering: Multilevel Approaches for Enhanced AAV Delivery on Friday, May 10th from 3:45pm to 4:00pm.

Dr. Ou's presentation will highlight Avirmax's proprietary novel capsid AAV2.N54, which was developed through capsid engineering. This capsid has shown significantly improved tropism to the macular retina compared to wildtype serotypes and AAV2.7m8 in various animal models including mice, rabbits, pigs, and non-human primates. This promising data has led Avirmax Biopharma to complete cGMP manufacturing of ABI-110 using their VSafTM rAAV Production Platform with Sf-rhabdovirus free Sf9 cells. The company is now preparing for regulatory submission for clinical investigations.

More on Marylandian
The second presentation by Dr. Ou is titled "Comprehensive Head-to-Head Comparisons Demonstrated Key Advantages of The Sf9 System Over HEK293 in rAAV Manufacturing." This will be a poster presentation during the AAV Vectors - Product Development Manufacturing and Approval Considerations session on Friday, May 10th at 12:00pm.

This presentation will focus on the systematic comparison between AAV vectors manufactured by the traditional HEK293 plasmid transfection system and the Sf9/baculoviral infection system. As shown in a publication from Avirmax in Molecular Therapy, the Sf9 system has demonstrated advantages in yields, full capsid ratio, aggregation, purity, and potency over traditional HEK293 systems.

Avirmax's presentations at the ASGCT annual meeting are highly anticipated and could potentially pave the way for new advancements in gene and cell therapy. With their innovative approach to capsid engineering and manufacturing processes, Avirmax is making significant strides towards improving treatments for wet AMD and PCV.
Filed Under: Business

Show All News | Report Violation


Latest on Marylandian